Onida, F, Sbianchi, G, Radujkovic, A, Sockel, K, Kroger, N, Sierra, J, Socie, G, Cornelissen, J, Poire, X, Raida, L, Bourhis, JH, Finke, J, Passweg, J, Salmenniemi, U, Schouten, HC, Beguin, Y, Martin, S, Deconinck, E, Ganser, A, Zver, S, Lioure, B, Rohini, R, Koster, L, Hayden, P, Iacobelli, S, Robin, M, Yakoub-Agha, I. Prognostic value of a new clinically-based classification system in patients with CMML undergoing allogeneic HCT: a retrospective analysis of the EBMT-CMWP. BONE MARROW TRANSPLANTATION. 2022; 57(6)DOI:10.1038/s41409-021-01555-9. PMID:35352038. IF:4.800(Q1/2D).

González-Muñoza C, Briones J, Sang Park H, García-Planella E. Marginal zone lymphoma under anti-TNF treatment in Crohn disease. Gastroenterologia y Hepatologia. 2022; 45(5)DOI:10.1016/j.gastrohep.2021.05.010. PMID:34118314. IF:1.900(Q4/10D).

Serna, N, Pallares, V, Unzueta, U, Garcia-Leon, A, Volta-Duran, E, Sanchez-Chardi, A, Parlade, E, Rueda, A, Casanova, I, Falgas, A, Alba-Castellon, L, Sierra, J, Villaverde, A, Vazquez, E, Mangues, R. Engineering non-antibody human proteins as efficient scaffolds for selective, receptor-targeted drug delivery. JOURNAL OF CONTROLLED RELEASE. 2022; 343DOI:10.1016/j.jconrel.2022.01.017. PMID:35051493. IF:10.800(Q1/1D).

Bataller, A, Garrido, A, Guijarro, F, Onate, G, Diaz-Beya, M, Arnan, M, Tormo, M, Vives, S, de Llano, MPQ, Coll, R, Gallardo, D, Vall-Llovera, F, Escoda, L, Garcia-Guinon, A, Salamero, O, Sampol, A, Merchan, BM, Bargay, J, Castano-Diez, S, Esteban, D, Oliver-Caldes, A, Rivero, A, Mozas, P, Lopez-Guerra, M, Pratcorona, M, Zamora, L, Costa, D, Rozman, M, Nomdedeu, JF, Colomer, D, Brunet, S, Sierra, J, Esteve, J. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Advances. 2022; 6(4)DOI:10.1182/bloodadvances.2021005585. PMID:34911079. IF:7.500(Q1/2D).

Pinana, JL, Garcia-Sanz, R, Martino, R, Garcia-Rao, M, Martin-Martin, GA, Risco-Galvez, I, Tormo, M, Martinez-Barranco, P, Marcos-Corrales, S, Calabuig, M, Conesa, V, Teruel, A, Ruiz-Perez, S, Solano, C, Navarro, D, Cedillo, A, Sureda, A. Booster effect after SARS-CoV-2 vaccination in immunocompromised hematology patients with prior COVID-19. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021006326. PMID:34905620. IF:7.500(Q1/2D).

Onate, G, Bataller, A, Garrido, A, Hoyos, M, Arnan, M, Vives, S, Coll, R, Tormo, M, Sampol, A, Escoda, L, Salamero, O, Garcia, A, Bargay, J, Aljarilla, A, Nomdedeu, JF, Esteve, J, Sierra, J, Pratcorona, M. Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2020004136. PMID:34516636. IF:7.500(Q1/2D).

Menghrajani, K, Gomez-Arteaga, A, Madero-Marroquin, R, Zhang, MJ, Bo-Subait, K, Sanchez, J, Wang, HL, Aljurf, M, Assal, A, Bacher, VU, Badawy, SM, Bejanyan, N, Bhatt, VR, Bredeson, C, Byrne, M, Castillo, P, Cerny, J, Chhabra, S, Ciurea, SO, DeFilipp, Z, Farhadfar, N, Gadalla, S, Gale, RP, Ganguly, S, Gowda, L, Grunwald, MR, Hashmi, S, Hildebrandt, G, Kanakry, CG, Kansagra, A, Khimani, F, Krem, M, Lazarus, H, Liu, HT, Martino, R, Michelis, FV, Nathan, S, Nishihori, T, Olsson, R, Reshef, R, Rizzieri, D, Rowe, JM, Savani, BN, Seo, S, Sharma, A, Solh, M, Ustun, C, Verdonck, LF, Hourigan, C, Sandmaier, B, Litzow, M, Kebriaei, P, Weisdorf, D, Zhang, YM, Tallman, MS, Saber, W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances. 2022; 6(3)DOI:10.1182/bloodadvances.2021004881. PMID:34551064. IF:7.500(Q1/2D).

Rule, S, Barreto, WG, Briones, J, Carella, AM, Casasnovas, O, Pocock, C, Wendtner, CM, Zaja, F, Robson, S, MacGregor, L, Tschopp, RR, Nick, S, Dreyling, M. Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the phase Ill MabCute study. HAEMATOLOGICA. 2022; 107(2)DOI:10.3324/haematol.2020.274803. PMID:34134469. IF:10.100(Q1/2D).